December 2, 2020 Amring Pharmaceuticals Inc., a generic pharmaceutical company, announced the acquisition of the global rights to LYSTEDA® (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy...
March 1, 2017 Amring Pharmaceuticals Inc. acquired six ANDA’s from Luitpold Pharmaceuticals, Inc. and AlphaForce, L.L.P., a joint venture between Luitpold Pharmaceuticals, Inc. and Alphagen Laboratories Inc. The acquired ANDAs include niche otic and ophthalmic...
Recent Comments